Summary of Key Points
The speed at which innovative drugs are included in medical insurance has increased, but patients often face the issue of being unable to get reimbursed for these medications. The root cause lies in the strict “restricted indications” for some insured drugs (especially those negotiated by the state), particularly those designated for use as second-line treatments. Additionally, the pace at which insurance reimbursement criteria are updated fails to keep up with changes in drug instructions and clinical guidelines. To prevent waste of funds due to improper reimbursement, the government uses an intelligent monitoring system consisting of two databases: a knowledge base and a rules database, to regulate doctors’ prescriptions. Doctors must consider both clinical efficacy and compliance with insurance regulations when prescribing drugs. For new indications to be covered by insurance, their clinical value and cost-effectiveness must be proven. However, a new policy that allows for “simple renewals” is helping to alleviate this issue. The focus of regulation is on ensuring the proper use of funds, not restricting the use of medications.
Detailed Explanation
Why Can't Insured Drugs Be Reimbursed? Restricted Indications Are a Major Barrier
Many insured drugs, especially those newly included in insurance through government negotiations, have specific reimbursement requirements. For example, they may only be used for children or for a limited number of treatment courses, or they may be designated as second-line treatments.
- What does “second-line use” mean? Simply put, these drugs can only be reimbursed if first-line treatments (such as metformin for diabetes) are ineffective or not tolerated by the patient.
- The Lag in Updates Is a Critical Problem: Drug instructions and clinical guidelines frequently add new indications. For instance, telaprevir was recently approved for use as a first-line treatment for type 2 diabetes, but insurance reimbursement criteria have not yet been updated accordingly. As a result, if a doctor prescribes telaprevir according to the new indication (as a first-line treatment), the patient will have to pay out of pocket.
The Insurance “Two Databases”: Intelligent “Supervisors” for Prescriptions
These two databases are central to the intelligent review of insurance claims. They act like a set of rules that guide doctors’ prescribing practices:
- Knowledge Base: This is like an encyclopedia containing all basic information on insurance policies, drug instructions, and treatment guidelines.
- Rules Database: Derived from the knowledge base, these rules define what constitutes compliant prescriptions. For example, prescribing a second-line drug without providing evidence that first-line treatments were ineffective is considered a violation.
Many hospitals across the country have integrated this system into their prescription systems. If a doctor violates the rules, the system will immediately issue a warning. If they continue to prescribe inappropriately and are caught during an inspection or a self-check by the insurance authority, they may face consequences. There are over 600 specific rules regarding restricted indications alone, ensuring meticulous oversight.
Doctors’ Dilemma: Balancing Clinical Efficacy and Insurance Compliance
Doctors need to balance two priorities when prescribing:
- They must choose the most appropriate drug based on the latest clinical guidelines and drug instructions (for example, using telaprevir as a first-line treatment when it is now approved for that purpose).
- They also need to comply with insurance regulations; otherwise, the insurance will not cover the cost, which could result in additional expenses for patients and potential penalties for doctors.
New Indications Need to Be Proven Worth the Cost
For new drug indications to be included in insurance reimbursement, they must meet certain criteria:
- Clinical Value: The new indication must be more effective or have fewer side effects compared to existing treatments.
- Health Economics: The cost of the treatment must be justified (i.e., it should provide better value for the money spent).
Good news is that an increasing number of newly negotiated drugs are now eligible for inclusion in insurance through a “simple renewal” process, which allows them to be added without significant price reductions. This gradually addresses the issue of drugs being available but not covered by insurance.
Regulation Is Not Designed to Restrict Doctors, but to Prevent Waste
The strict regulations are in place because previous inspections revealed widespread cases of improper reimbursement. Doctors often prescribed second-line drugs without first trying first-line options, leading to unnecessary expensive treatments and waste of insurance funds. The purpose of the two databases is to provide doctors with clear information in advance about what is covered by insurance, not to restrict their use of new drugs. The insurance authority has made it clear that the scope of coverage determines when funds will be disbursed, not to limit clinical choices.
In summary, the restrictions on insurance reimbursement are not intended to deliberately cause inconvenience for patients but to ensure that funds are used efficiently. Both doctors and patients can understand the reasons behind these restrictions and know where to seek help if they encounter reimbursement issues.